<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsFei Su, Jeffrey A. Sosman, Paul B. Chapman et al.|New England Journal of Medicine|2012Cited by 1k
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant MelanomaMaría Romina Girotti, Caroline J. Springer|Cancer Cell|2014Cited by 209
Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugatesPeter D. Senter, Caroline J. Springer|Advanced Drug Delivery Reviews|2001Cited by 177
A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAFSteven R. Whittaker, Caroline J. Springer|Cancer Research|2010Cited by 25
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancersG. Saturno, Caroline J. Springer, Filipa M. Lopes et al.|Annals of Oncology|2020Cited by 21